251 related articles for article (PubMed ID: 15061240)
1. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Heresco-Levy U; Javitt DC
Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
[TBL] [Abstract][Full Text] [Related]
2. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
[TBL] [Abstract][Full Text] [Related]
3. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
4. Effects of D-cycloserine on negative symptoms in schizophrenia.
Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
[TBL] [Abstract][Full Text] [Related]
5. Treatment of negative and cognitive symptoms.
Javitt DC
Curr Psychiatry Rep; 1999 Oct; 1(1):25-30. PubMed ID: 11122902
[TBL] [Abstract][Full Text] [Related]
6. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Javitt DC
Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of negative symptoms in schizophrenia by glycine.
Javitt DC; Zylberman I; Zukin SR; Heresco-Levy U; Lindenmayer JP
Am J Psychiatry; 1994 Aug; 151(8):1234-6. PubMed ID: 8037263
[TBL] [Abstract][Full Text] [Related]
8. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.
Tuominen HJ; Tiihonen J; Wahlbeck K
Schizophr Res; 2005 Jan; 72(2-3):225-34. PubMed ID: 15560967
[TBL] [Abstract][Full Text] [Related]
9. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
Goff DC; Tsai G; Manoach DS; Coyle JT
Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
[TBL] [Abstract][Full Text] [Related]
10. Glycine modulators in schizophrenia.
Javitt DC
Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
[TBL] [Abstract][Full Text] [Related]
11. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.
Heresco-Levy U; Silipo G; Javitt DC
Psychopharmacol Bull; 1996; 32(4):731-40. PubMed ID: 8993096
[TBL] [Abstract][Full Text] [Related]
12. Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex.
Fujihira T; Kanematsu S; Umino A; Yamamoto N; Nishikawa T
Neurochem Int; 2007; 51(2-4):233-6. PubMed ID: 17662507
[TBL] [Abstract][Full Text] [Related]
13. D-alanine added to antipsychotics for the treatment of schizophrenia.
Tsai GE; Yang P; Chang YC; Chong MY
Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
[TBL] [Abstract][Full Text] [Related]
15. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.
Cascella NG; Macciardi F; Cavallini C; Smeraldi E
J Neural Transm Gen Sect; 1994; 95(2):105-11. PubMed ID: 7865165
[TBL] [Abstract][Full Text] [Related]
16. D-serine added to clozapine for the treatment of schizophrenia.
Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
[TBL] [Abstract][Full Text] [Related]
17. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
Tsai GE; Lin PY
Curr Pharm Des; 2010; 16(5):522-37. PubMed ID: 19909229
[TBL] [Abstract][Full Text] [Related]
18. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Tsai G; Lane HY; Yang P; Chong MY; Lange N
Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
Shim SS; Hammonds MD; Kee BS
Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
[TBL] [Abstract][Full Text] [Related]
20. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
Semba J
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
